Unveiling the Surprising Self-Teamwork of a Protein Regulator: A New Pathway for Disease Treatment
Uncover the hidden potential of a protein regulator's self-teamwork and its impact on disease treatment.
A groundbreaking discovery by Penn State researchers reveals a surprising twist in the role of a key protein regulator. This protein, known for its crucial role in maintaining balance in the body's fat, glucose, and cholesterol levels, has been found to work not only with another protein but also with itself. The team's research, published in the journal Nucleic Acids Research, sheds light on the structure and function of this unique protein pairing, offering new insights into potential therapeutic targets for liver cancer, diabetes, and other metabolic diseases.
The farnesoid X receptor (FXR) protein, primarily found in the liver, kidneys, and intestine, is a master regulator of lipid, glucose, and bile acid levels. Typically, it partners with the retinoid X receptor alpha (RXR) to bind to specific DNA sequences and function as a receptor for ligands. This partnership activates genes involved in bile acid synthesis, thereby regulating lipid and glucose metabolism.
However, the researchers were intrigued by the possibility of FXR working with itself. In their experiments, they combined purified FXR with synthetic DNA segments and confirmed that FXR can bind to DNA as a single molecule or in pairs. The team then demonstrated that the FXR-FXR pairing could recruit and bind to cellular components, driving gene expression.
The real surprise came when they used small-angle X-ray scattering to characterize the three-dimensional structure of the FXR-FXR complex. Unlike the FXR-RXR pair, the molecules in the FXR-FXR complex adopt an extended conformation, with the ligand-binding regions separated and not interacting. This unusual structure suggests that the FXR-FXR pairing may regulate a different set of genes, opening up new avenues for therapeutic intervention.
Denise Okafor, the research team leader, emphasizes the potential implications of this discovery. "We could be uncovering a hidden function of this receptor that has been masked all these years because we thought its function was defined by its partnership with RXR. Because FXR is so fundamentally involved in the liver and liver disease, diabetes, and other metabolic diseases, there's just so much to understand about this newly characterized structural variant."
The research team, including Neela Yennawar and Sabab Hasan Khan, believes that further exploration of this structural variant could lead to new treatments for diseases associated with FXR. The discovery not only highlights the complexity of protein interactions but also offers a fresh perspective on disease treatment, inviting further discussion and research in this exciting area.
